| Target ID: | dt58 |
|---|---|
| CID: | 1049 |
| Compound Name: | Pyridine |
| Gene ID: | 1544 |
| Gene Name: | CYP1A2 |
| Species: | Rattus norvegicus (Norway rat) |
| PubMed IDs: | -- |
| Action: | Pyridine results in increased expression of CYP1A2 mRNA |
Knowledge Graph
| Target ID | CID | Compound Name | Gene ID | Gene Name | Species | Action | |
|---|---|---|---|---|---|---|---|
| dt1152 | 54678486 | Warfarin | 1544 | CYP1A2 | Homo sapiens (human) | Substrate | Details |
| dt1334 | 5339 | Sulfasalazine | 1544 | CYP1A2 | Homo sapiens (human) | -- | Details |
| dt168 | 3365 | Fluconazole | 1544 | CYP1A2 | Homo sapiens (human) | -- | Details |
| dt229 | 4030 | Mebendazole | 1544 | CYP1A2 | Homo sapiens (human) | -- | Details |
| dt290 | 4477 | Niclosamide | 1544 | CYP1A2 | Homo sapiens (human) | -- | Details |
| dt310 | 4595 | Ondansetron | 1544 | CYP1A2 | Homo sapiens (human) | CYP1A2 protein affects the metabolism of ondansetron | Details |
| dt363 | 5743 | Dexamethasone | 1544 | CYP1A2 | Homo sapiens (human) | -- | Details |
| dt508 | 33613 | Amoxicillin | 1544 | CYP1A2 | Homo sapiens (human) | -- | Details |
| dt57 | 1049 | Pyridine | 1544 | CYP1A2 | Rattus norvegicus (Norway rat) | Pyridine results in increased activity of CYP1A2 protein|pyridine results in increased expression of CYP1A2 protein | Details |
| dt644 | 449193 | Roflumilast | 1544 | CYP1A2 | Homo sapiens (human) | Substrate | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| Drug7 | PYRIDINE | Chemical drug | -- | -- | -- | Under clinical trials | Details |
| Compound ID | Source ID | Source Type | Compound Name | Molecular Weight | Molecular Formula | Molecular Species | |
|---|---|---|---|---|---|---|---|
| No data available | |||||||
| Disease ID | Disease Name | Definition | Mechanism | |
|---|---|---|---|---|
| No data available | ||||
| Strategy ID | Therapy Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||